Le Lézard
Classified in: Health

AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death


AbbVie faces lawsuit over Zymaxidtm.

MCKINNEY, Texas, July 2, 2024 /PRNewswire-PRWeb/ -- Wormington & Bollinger is actively reviewing product liability cases associated with antibiotic eyedrops causing Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

AbbVie, Inc. (NYSE: ABBV), a pharmaceutical company headquartered in Chicago, Illinois, is facing a product liability lawsuit, filed by plaintiff, Alicia Burton in Los Angeles, California. Burton alleges that she sustained catastrophic injuries stemming from the use of AbbVie's ophthalmic medication, Zymaxidtm (topical gatifloxacin).

In Alicia Burton v. Allergan, Inc. and AbbVie, Inc. Case No. 2:22-cv-05920 in the U.S. District Court for the Central District of California, the plaintiff alleges that she suffered from SJS and TEN in 2019 after using AbbVie's Zymaxidtm eye drops. This resulted in severe ocular injuries, disfiguring scarring and permanently disabling injuries.

SJS and TEN are severe life-threatening reactions to medications with mortality rates as high as 70%, often resulting in permanent blindness, skin detachment, and irreversible physical disfigurement from burns.

AbbVie's prescription medication, Zymaxidtm, is a quinolone antibiotic in eye drop form. While antibiotics taken orally and by IV have been long implicated as a common cause of SJS and TEN, cases caused by eye drop formulations of different antibiotics are on the rise.

AbbVie manufactures antibiotic eye drops marketed under the following trade names: Zymaxidtm, Zymartm, Ocufloxtm, Bleph-10tm, and Blephamidetm.

Consumers should seek medical attention immediately upon experiencing any of the symptoms listed above. Consumers experiencing SJS and TEN caused by antibiotic eyedrops or other prescription drugs are urged to contact Wormington & Bollinger for a free case evaluation.

About Wormington & Bollinger

Lennie F. Bollinger is an attorney headquartered in McKinney, Texas. Mr. Bollinger serves clients across the U.S. in cases involving personal injury, medical malpractice, pharmaceutical and drug-device litigation, truck wrecks, product liability, premises liability, and multi-district litigation.

Media Contact

Jeremy Friesen, Wormington & Bollinger, 1 888-967-6529, [email protected], https://www.wormingtonlegal.com/

SOURCE AbbVie, Inc.


These press releases may also interest you

at 15:04
In the news release, Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw, issued 02-Jul-2024 by Menarini Silicon Biosystems over PR Newswire,...

at 14:53
The Alzheimer's Association celebrates today's U.S. Food and Drug Administration (FDA) action to approve Kisunlatm (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer's disease, which includes mild cognitive...

at 14:45
Alleva, a premier provider of electronic medical record (EMR) software solutions tailored for the behavioral health and addiction recovery sectors, is proud to announce its inclusion in the Software Advice FrontRunners for HIPAA Compliance Software...

at 14:37
Statement attributable to:Octavia Peck Palmer, PhDPresident, Association for Diagnostics & Laboratory Medicine (formerly AACC) "On June 28, in Loper Bright Enterprises v. Raimondo, the Supreme Court overturned the so-called Chevron doctrine and...

at 14:24
NanoCellect Biomedical, a leader in microfluidic cell sorting technology, proudly announces the launch of VERLOtm Image-Guided Cell Sorter, a groundbreaking cell sorter poised to redefine the landscape of single-cell visualization and gentle flow...

at 14:00
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today...



News published on and distributed by: